{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T13:08:06Z","timestamp":1777900086137,"version":"3.51.4"},"reference-count":47,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Life"],"abstract":"<jats:p>Background: Neovascular age-related macular degeneration (nAMD) is a progressive chronic disease that represents a major cause of irreversible vision loss worldwide. In this study we aim to assess the short-term functional and anatomical outcomes of brolucizumab therapy in treatment-na\u00efve patients with nAMD presenting with low baseline visual acuity in a single institution setting. Methods: This is a prospective non-randomized study that included 154 treatment-na\u00efve eyes with low baseline visual acuity. We measured visual outcomes (BCVA, logMAR) and structural outcomes (CST, \u03bcm). We also stratified the study population into respective age subgroups to evaluate any possible trend between outcome changes and age differences. BCVA and CST were measured at baseline, at each consecutive month (month 1, 2 and 3) of the loading phase, as well as at the final timepoint (6 months). Intraocular pressure (IOP) before and after injection, as well as the incidence of serious adverse events, were monitored throughout the study. Results: Mean BCVA improved by 0.41 logMAR (+20 ETDRS letters) after the first injection, 0.65 logMAR (+32 letters) after the second, and reached a maximum improvement of 0.80 logMAR after the third injection. The most important BCVA improvement was seen in younger patients (&lt;50 years), with mean BCVA decreasing from approximately 1.0 logMAR at baseline to around 0.3\u20130.4 logMAR at the final measurement. Mean CST declined by 45.5 \u03bcm after the first injection, 78.5 \u03bcm after the second, 117.8 \u03bcm after the third, and 143.6 \u03bcm at the final timepoint, indicating a pronounced anatomical response to intravitreal brolucizumab therapy. Conclusions: In conclusion, this study demonstrates that brolucizumab therapy provides significant short-term anatomical and functional improvements in treatment-na\u00efve patients with nAMD and poor baseline visual acuity. Baseline visual acuity, treatment-na\u00efve status, and patient age appear to be key determinants of visual gain.<\/jats:p>","DOI":"10.3390\/life16050754","type":"journal-article","created":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T10:15:27Z","timestamp":1777630527000},"page":"754","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-World Experience with Brolucizumab in Treatment-Na\u00efve nAMD with Low Baseline Visual Acuity: Short-Term Outcomes from a Prospective Single-Institution Study"],"prefix":"10.3390","volume":"16","author":[{"given":"Arsim","family":"Hajdari","sequence":"first","affiliation":[{"name":"Italian Eye Hospital, 10000 Prishtina, Kosovo"},{"name":"Department of Life Sciences, University of Business and Technology, 10000 Prishtina, Kosovo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3141-732X","authenticated-orcid":false,"given":"Valdet","family":"Uka","sequence":"additional","affiliation":[{"name":"Division of Pharmacy, Faculty of Medicine, University of Prishtina, 10000 Prishtina, Kosovo"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,5,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/nrd.2015.17","article-title":"Ten years of anti-vascular endothelial growth factor therapy","volume":"15","author":"Ferrara","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s00109-013-0993-5","article-title":"Ocular neovascularization","volume":"91","author":"Campochiaro","year":"2013","journal-title":"J. Mol. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1016\/S0140-6736(12)60282-7","article-title":"Age-related macular degeneration","volume":"379","author":"Lim","year":"2012","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","article-title":"Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040","volume":"2","author":"Wong","year":"2014","journal-title":"Lancet Glob. Health"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1001\/jama.2023.26074","article-title":"Age-related macular degeneration: A review","volume":"331","author":"Fleckenstein","year":"2024","journal-title":"JAMA"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.preteyeres.2017.11.003","article-title":"Optical coherence tomography angiography","volume":"64","author":"Spaide","year":"2018","journal-title":"Prog. Retin. Eye Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa054481","article-title":"Ranibizumab for neovascular age-related macular degeneration","volume":"355","author":"Rosenfeld","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1056\/NEJMoa062655","article-title":"Ranibizumab versus verteporfin for neovascular age-related macular degeneration","volume":"355","author":"Brown","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","article-title":"Intravitreal aflibercept in wet age-related macular degeneration","volume":"119","author":"Heier","year":"2012","journal-title":"Ophthalmology"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/j.ophtha.2015.05.010","article-title":"Long-term outcomes of treatment of neovascular age-related macular degeneration","volume":"122","author":"Gillies","year":"2015","journal-title":"Ophthalmology"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1136\/bjophthalmol-2014-305327","article-title":"Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration","volume":"99","author":"Holz","year":"2015","journal-title":"Br. J. Ophthalmol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ophtha.2019.04.017","article-title":"HAWK and HARRIER: Phase 3 trials of brolucizumab for neovascular AMD","volume":"127","author":"Dugel","year":"2020","journal-title":"Ophthalmology"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/s41433-019-0583-z","article-title":"Brolucizumab\u2014leading an era of structural revolution for long-term VEGF suppression","volume":"34","author":"Sharma","year":"2020","journal-title":"Eye"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/S0140-6736(22)00010-1","article-title":"Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): Two randomised, double-masked, phase 3, non-inferiority trials","volume":"399","author":"Heier","year":"2022","journal-title":"Lancet"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S0140-6736(22)00018-6","article-title":"Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): Two randomised, double-masked, phase 3 trials","volume":"399","author":"Wykoff","year":"2022","journal-title":"Lancet"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2861","DOI":"10.2147\/DDDT.S427416","article-title":"Faricimab: Transforming the future of macular diseases treatment\u2014A comprehensive review of clinical studies","volume":"17","author":"Panos","year":"2023","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1080\/14712598.2021.1915278","article-title":"Brolucizumab: A novel anti-VEGF humanized single-chain antibody fragment for treating wet age-related macular degeneration","volume":"21","author":"Traverso","year":"2021","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_18","unstructured":"U.S. Food and Drug Administration (2026, February 25). FDA Approves Brolucizumab-Dbll (Beovu) for Neovascular (Wet) Age-Related Macular Degeneration, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2019\/761125Orig1s000ltr.pdf."},{"key":"ref_19","unstructured":"European Medicines Agency (2026, February 25). Beovu (Brolucizumab): EPAR\u2014Public Assessment Report. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/beovu."},{"key":"ref_20","unstructured":"U.S. Food and Drug Administration (2026, February 25). FDA Approves Beovu (Brolucizumab-Dbll) 6 mg for Diabetic Macular Edema, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/761125s008lbl.pdf."},{"key":"ref_21","unstructured":"European Commission (2026, February 25). Community Register of Medicinal Products for Human Use: Beovu (Brolucizumab)\u2014Extension of Indication for Diabetic Macular Oedema. Available online: https:\/\/ec.europa.eu\/health\/documents\/community-register\/html\/h1417.htm."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ophtha.2020.06.028","article-title":"HAWK and HARRIER: Ninety-six-week outcomes from the phase 3 trials of brolucizumab in neovascular age-related macular degeneration","volume":"128","author":"Dugel","year":"2021","journal-title":"Ophthalmology"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Musia\u0142-Kopiejka, M., Polanowska, K., Dobrowolski, D., Krysik, K., Wyl\u0119ga\u0142a, E., Grabarek, B.O., and Lyssek-Boro\u0144, A. (2022). The effectiveness of brolucizumab and aflibercept in patients with neovascular age-related macular degeneration. Int. J. Environ. Res. Public Health, 19.","DOI":"10.3390\/ijerph19042303"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1038\/s41433-022-02092-5","article-title":"Efficacy and safety of brolucizumab versus aflibercept in eyes with early persistent retinal fluid: 96-week outcomes from HAWK and HARRIER","volume":"37","author":"Lally","year":"2023","journal-title":"Eye"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1097\/APO.0000000000000602","article-title":"Review on the safety and efficacy of brolucizumab for neovascular age-related macular degeneration from major studies and real-world data","volume":"12","author":"Radke","year":"2023","journal-title":"Asia Pac. J. Ophthalmol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Alali, N.M., Aljahdali, A., AlBalawi, H.B., Al Jarallah, O.J., Al Zaid, S.M., Abuallut, I., ALMarek, F., Shajry, I., Alotaibi, Y.A., and Hazzazi, M.A. (2025). Effectiveness, safety, and real-world experience of brolucizumab: A systematic review. Pharmaceuticals, 18.","DOI":"10.3390\/ph18111620"},{"key":"ref_27","unstructured":"R Core Team (2025). R: A Language and Environment for Statistical Computing, R Foundation for Statistical Computing. Available online: https:\/\/www.R-project.org\/."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"The CATT Research Group (2011). Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N. Engl. J. Med., 364, 1897\u20131908.","DOI":"10.1056\/NEJMoa1102673"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/j.ophtha.2014.05.009","article-title":"Twenty-four-month efficacy and safety of ranibizumab for neovascular age-related macular degeneration","volume":"121","author":"Ho","year":"2014","journal-title":"Ophthalmology"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1016\/j.ophtha.2015.08.015","article-title":"Association of baseline characteristics and early vision response with two-year vision outcomes in the comparison of AMD treatments trials (CATT)","volume":"122","author":"Ying","year":"2015","journal-title":"Ophthalmology"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.preteyeres.2017.12.002","article-title":"Real-world outcomes in patients with neovascular age-related macular degeneration treated with intravitreal vascular endothelial growth factor inhibitors","volume":"65","author":"Mehta","year":"2018","journal-title":"Prog. Retin. Eye Res."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Lee, Y.J., Kang, S., Won, J.Y., Roh, Y.J., Ra, H., Lee, M.Y., Park, S.P., and Jee, D.H. (2024). Real-world visual acuity outcomes for patients with treatment-na\u00efve neovascular age-related macular degeneration receiving anti-VEGF therapy. PLoS ONE, 19.","DOI":"10.1371\/journal.pone.0310381"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/s00417-016-3507-7","article-title":"A modified treat-and-extend regimen of aflibercept for treatment-na\u00efve patients with neovascular age-related macular degeneration","volume":"255","author":"Ohnaka","year":"2017","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s00417-023-06241-8","article-title":"Comparison of functional and morphologic changes between brolucizumab and faricimab in neovascular age-related macular degeneration","volume":"262","author":"Yanagi","year":"2024","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/j.ophtha.2017.03.057","article-title":"Brolucizumab versus aflibercept in participants with neovascular age-related macular degeneration: A randomized trial","volume":"124","author":"Dugel","year":"2017","journal-title":"Ophthalmology"},{"key":"ref_36","first-page":"11621317","article-title":"Comparative efficacy and safety of anti-vascular endothelial growth factor agents for neovascular age-related macular degeneration: A network meta-analysis","volume":"14","author":"Sun","year":"2024","journal-title":"Sci. Rep."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"118881","DOI":"10.1016\/j.biopha.2025.118881","article-title":"Comparative effectiveness and safety landscape of anti-VEGF therapies for neovascular age-related macular degeneration: Systematic review and network meta-analysis","volume":"196","author":"Chen","year":"2026","journal-title":"Biomed. Pharmacother."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1159\/000513048","article-title":"Brolucizumab: A newly developed anti-VEGF molecule for the treatment of neovascular age-related macular degeneration","volume":"244","author":"Tadayoni","year":"2021","journal-title":"Ophthalmologica"},{"key":"ref_39","first-page":"218","article-title":"Correlation of change in central subfield thickness and change in visual acuity in neovascular age-related macular degeneration: Post hoc analysis of VIEW 1 and 2","volume":"235","author":"Nanegrungsunk","year":"2022","journal-title":"Am. J. Ophthalmol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/j.oret.2021.02.012","article-title":"Longitudinal assessment of ellipsoid zone integrity, subretinal hyperreflective material, and sub-retinal pigment epithelium disease in neovascular age-related macular degeneration","volume":"5","author":"Ehlers","year":"2021","journal-title":"Ophthalmol. Retin."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"3243","DOI":"10.1038\/s41433-024-03308-6","article-title":"Fibrosis in age-related neovascular macular degeneration in the anti-VEGF era","volume":"38","author":"Chakravarthy","year":"2024","journal-title":"Eye"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1111\/ceo.13927","article-title":"Association between retinal thickness variation and visual acuity change in neovascular age-related macular degeneration","volume":"49","author":"Cheong","year":"2021","journal-title":"Clin. Exp. Ophthalmol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e027441","DOI":"10.1136\/bmjopen-2018-027441","article-title":"One- and two-year visual outcomes from the Moorfields age-related macular degeneration database: A retrospective cohort study and an open science resource","volume":"9","author":"Fasler","year":"2019","journal-title":"BMJ Open"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/j.ophtha.2020.11.011","article-title":"Risk of inflammation, retinal vasculitis, and retinal occlusion-related events with brolucizumab: Post hoc review of HAWK and HARRIER","volume":"128","author":"Srivastava","year":"2021","journal-title":"Ophthalmology"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1001\/jamaophthalmol.2021.4585","article-title":"Safety outcomes of brolucizumab in neovascular age-related macular degeneration: Results from the IRIS Registry and Komodo Healthcare Map","volume":"140","author":"Khanani","year":"2022","journal-title":"JAMA Ophthalmol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1007\/s40123-024-00920-3","article-title":"Real-world safety outcomes with brolucizumab in neovascular age-related macular degeneration: Findings from the IRIS Registry","volume":"13","author":"Zarbin","year":"2024","journal-title":"Ophthalmol. Ther."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Kin, A., Mizukami, T., Ueno, S., Mishima, S., and Shimomura, Y. (2024). Short-term comparison of switching to brolucizumab or faricimab from aflibercept in neovascular AMD patients. Medicina, 60.","DOI":"10.20944\/preprints202406.1712.v1"}],"container-title":["Life"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-1729\/16\/5\/754\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T10:22:34Z","timestamp":1777630954000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-1729\/16\/5\/754"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,1]]},"references-count":47,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["life16050754"],"URL":"https:\/\/doi.org\/10.3390\/life16050754","relation":{},"ISSN":["2075-1729"],"issn-type":[{"value":"2075-1729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,1]]}}}